Challenge
In over hundreds of gene therapy clinical trials, viral vectors such as Adeno-Associated Viruses (AAVs) are used to deliver healthy genes directly into cells, offering the potential to cure diseases, not just treat the symptoms.
But making these AAVs still rely on outdated, cell-based systems built for another era. The result: inconsistent quality, low potency, and slow, expensive development that holds back the field.
Solution
At Fuse, we make AAVs outside the cell.
Fuse cell-free technology replaces standard cell-based process with a precise enzymatic system that produces high-quality AAVs in a single step, delivering >99% filled capsids with unmatched purity and consistency.
Vision
We aim to redefine how gene therapies are made, to build a future where safe, potent, and scalable treatments reach patients faster.
No cells. No bottlenecks. Just a faster path to better gene therapies.
